Company Overview of aTyr Pharma Inc.
aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
Total Annual Compensation: $410.0K
Chief Medical Officer
Total Annual Compensation: $265.2K
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Inc. Announces Executive Changes
Jul 20 15
aTyr Pharma Inc. announced that it will transition oversight of clinical development and operations to Ms. Kelly Blackburn and Melissa Ashlock, M.D. as David Weiner, M.D., transitions from his current position as aTyr's Chief Medical Officer into a clinical advisory role through the end of the first quarter of 2016.
aTyr Pharma, Inc. Announces Resignation of President and Chief Operating Officer Frederic Chereau
Jul 13 15
aTyr Pharma Inc. announced the resignation of President and Chief Operating Officer Frederic Chereau to pursue other opportunities, effective immediately.
aTyr Pharma Inc.(NasdaqGS:LIFE) added to Russell 2000 Index
Jun 30 15
aTyr Pharma Inc. will be added to Russell 2000 Index
Similar Private Companies By Industry
Recent Private Companies Transactions
March 31, 2015
Most Searched Private Companies
Sponsored Financial Commentaries